Oct 1, 2024

ILiAD Biotechnologies to Participate in Upcoming Investor Conferences

Aug 5, 2024

Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15

Jun 24, 2024

ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine

May 28, 2024

ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine

Oct 18, 2023

ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona

Sept 5, 2023

ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine

Apr 5, 2023

ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress

Mar 10, 2023

ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet

Sep 6, 2022

ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine

Jun 27, 2022

ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium

Apr 26, 2022

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

Jan 3, 2022

FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1

Dec 17, 2021

ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial

Sep 29, 2021

ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis

Oct 21, 2020

ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting

Sep 29, 2020

ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

Sep 24, 2020

ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress

Nov 19, 2019

Dr. Cheryl Keech Joins ILiAD Biotechnologies as Chief Medical Officer and Executive VP of Clinical Research

Oct 8, 2019

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial

Jun 25, 2019

ILiAD Biotechnologies Announces First Patient Enrolled in BPZE1 Pertussis Vaccine Multicenter Phase 2b Clinical Trial

Dec 19, 2018

ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center

May 15, 2018

NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University

July 5, 2017

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

February 19, 2016

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups

January 8, 2014

ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology